Clinical evidence (Shaw et al., 2014; Shaw et al., 2019) confirms that ROS1 fusion-positive NSCLC patients treated with crizotinib achieve an objective response rate (ORR) of 72%, with median progression-free survival (mPFS) of 19.3 months and median overall survival (mOS) of 51.4 months, demonstrating favorable safety profiles (incidence of grade ≥3 adverse events <10%). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.